Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MediClin AGXTER:MED +0.92%75 Debt-to-Equity is 1.42 as of Jun. 2026, which is 35% below its 10-year median of 2.20. GuruFocus rates XTER:MED with a GF Score™ of 75/100 and a GF Value™ of €3.20 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 564 Healthcare Providers & Services companies, MediClin AG ranks worse than 81.38% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for MediClin AG's Debt-to-Equity or its related term are showing as below:
XTER:MED'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27 Med: 2.2 Max: 2.82
Current: 1.42
During the past 13 years, the highest Debt-to-Equity Ratio of MediClin AG was 2.82. The lowest was 0.27. And the median was 2.20.
XTER:MED's Debt-to-Equity is ranked worse than 81.38% of 564
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs XTER:MED: 1.42
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
MediClin AG Debt-to-Equity Related Terms
MediClin AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for MediClin AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:MED vs HCA, THC, DVA: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, MediClin AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MediClin AG Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MediClin AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where MediClin AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MediClin AG (XTER:MED) has a Debt-to-Equity of 1.42 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediClin AG and its competitors. This is 35% below median its historical median of 2.20. Over the past decade, MediClin AG's Debt-to-Equity has ranged from 0.27 to 2.82. According to the industry distribution chart, MediClin AG ranks #459 out of 564 companies in the Healthcare Providers & Services industry, placing it in the top 81.4%.
Is MediClin AG's Debt-to-Equity too high?
MediClin AG's current Debt-to-Equity of 1.42 is 35% below median its 10-year median of 2.20. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 2.82. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. MediClin AG's value of 1.42 is 238.1% above this industry median. Based on the distribution chart, MediClin AG ranks #459 out of 564 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, MediClin AG has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does MediClin AG's Debt-to-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, MediClin AG ranks #459 out of 564 companies for Debt-to-Equity. This places MediClin AG in the lower half of its industry. The industry median Debt-to-Equity is 0.42. MediClin AG's value of 1.42 is 238.1% above this benchmark. Historically, MediClin AG's own Debt-to-Equity has ranged from 0.27 to 2.82 over the past decade. While the company's 10-year median is 2.20 vs. the industry median of 0.42, MediClin AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MediClin AG's current Debt-to-Equity of 1.42 is 238.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MediClin AG and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MediClin AG's current Debt-to-Equity is 1.42, which is 35% below median its own 10-year median of 2.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MediClin AG stock overvalued right now?
Based on GuruFocus' analysis, MediClin AG (XTER:MED) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.20, compared to a current price of €5.50 — trading 71.9% above its estimated fair value. The current Debt-to-Equity is 1.42, which is 35% below median its 10-year median of 2.20 and 238.1% above the Healthcare Providers & Services industry median of 0.42. MediClin AG's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MediClin AG (XTER:MED), the current Debt-to-Equity is 1.42 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MediClin AG (XTER:MED) Overvalued in 2026?
Based on GuruFocus' analysis, MediClin AG stock appears to be overvalued.
The current stock price of €5.50 is trading 71.9% above its estimated GF Value™ of €3.20.
GuruFocus considers MediClin AG to be Significantly Overvalued.
Key valuation signals for XTER:MED:
Debt-to-Equity: 1.42 (35% below median its 10-year median of 2.20)
GF Value™: €3.20 vs. price of €5.50 (71.9% above fair value)
Industry Position: 238.1% above the Healthcare Providers & Services median (#459 of 564)
No single metric tells the full story. See the XTER:MED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
75GF Score
Get the complete analysis for XTER:MED
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:MED has been successfully added to your 
